If you have been reading about research chemical and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-25. Numbers and descriptions here follow the published literature rather than marketing material.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
Sulfonylureas bind to and close ATP-sensitive K+ (KATP) channels on the cell membrane of pancreatic beta cells, which depolarizes the cell by preventing potassium from exiting. This depolarization opens voltage-gated Ca2+ channels. The rise in intracellular calcium leads to increased fusion of insulin granules with the cell membrane, and therefore increased secretion of mature insulin. There is some evidence that sulfonylureas also sensitize β-cells to glucose, that they limit glucose production in the liver, that they decrease lipolysis (breakdown and release of fatty acids by adipose tissue) and decrease clearance of insulin by the liver. The KATP channel is an octameric complex of the inward-rectifier potassium ion channel Kir6.x and sulfonylurea receptor SUR which associate with a stoichiometry of 4:4. Furthermore, it has been shown that sulfonylureas interact with the nucleotide exchange factor Epac2. Mice lacking this factor exhibited a decreased glucose-lowering effect upon sulfonylurea treatment.
The People's Armed Police Forestry Corps (Chinese: 武警森林部队) was a former branch of the PAP which did tasks such as fighting Wildfires and law enforcement in forest areas, along with protecting wildlife, disaster relief. When it was active, it was the only military branch on Earth whose task was fighting wildfires. It was nicknamed the "Fearless Red Boys". The Forestry Corps was officially disbanded on 10 October 2018.
==== Stimuli-responsive nanogels for drug delivery ==== Nanogels that respond to various stimuli including changes in pH and temperature or the presence of redox and light cues have proven to be useful tools for drug delivery. One such responsive nanogel was designed to switch from a surface negative charge to a surface positive charge upon exposure to decrease in pH once inside a tumor. When loaded with a chemotherapeutic agent, this technology induced a lower viability in 3D tumor spheroids compared to control groups. Another type of nanogel loaded with osteoarthritis anti-inflammatory drugs was found to significantly increase the amount of drug transported after topical application to the skin and exposure to its natural elevated temperature. One group reported a method to control the release rate of an antiplatelet medication from a nanogel by using UV light to alter the crosslinking density of the polymer and subsequently change the swelling rate. Additionally, other nanogels have been synthesized to include disulfide cleavable polymers that respond to reductive cues in the surrounding environment. One such nanogel was loaded with a chemotherapeutic agent and demonstrated a decrease in cell viability compared to a free version of the same agent.
Freight technology in air cargo is already critically important in cold chain management for sensitive goods such as agricultural products, vaccines, and medications. Monitoring in the form of data loggers can record temperature, light, humidity, and GPS location to show whether goods have been improperly cooled, handled, or tampered with. It is estimated that billions of dollars in revenue are lost by cargo companies annually due to dispute resolution for shipment delays and lost and damaged goods. The world’s first blockchain-based system for streamlining air cargo costing, billing, and reconciliation was announced at the 2019 IATA World Cargo Symposium.
Sources: en.wikipedia.org
When archaic spiders moved from the water to the land in the Early Devonian period, they started making silk to protect their bodies and their eggs. Most spiders have appendages called spinnerets. These are organs that produce silk with which the spiders spin webs (although some use the silk to catch their prey in other ways). Spiders gradually started using silk for hunting purposes, first as guide lines and signal lines, then as ground or bush webs, and eventually as the aerial webs that are currently familiar. Spiders produce silk from their spinneret glands located at the tip of their abdomen. Each gland produces a thread for a special purpose – for example a trailed safety line, sticky silk for trapping prey or fine silk for wrapping it. Spiders use different gland types to produce different silks, and some spiders are capable of producing up to eight different silks during their lifetime. Most spiders have three pairs of spinnerets, each having its own function – there are also spiders with just one pair and others with as many as four pairs. Webs allow a spider to catch prey without having to expend energy by running it down, making it an efficient method of gathering food. The hair and claws on spiders' legs allow them to cling to their webs. The oils on their bodies keep them from sticking to their own webs. However these energy savings are somewhat offset by the fact that constructing the web is in itself energetically costly, due to the large amount of protein required in the form of silk.
== MTRR gene == The Methionine Synthase Reductase (MTRR) gene primarily acts in the reductive regeneration of cob(I)alamin (vitamin B12). Cob(I)alamin is a cofactor that maintains activation of the methionine synthase enzyme (MTR) methionine synthase, linking folate and methionine metabolism. Donation of methyl groups from folate are utilized for cellular and DNA methylation, influencing epigenetic inheritance.
During the Migration Period, the Jutland peninsula was home to several tribes. The Jutes inhabited the most northern part of the peninsula from Grenen to Olger's Dyke. This dyke, dating back to around the first century, served as the boundary between the Jutes in the north and the Angles in the south. This dyke lost its relevance in the 200s when the Angles expanded northward, leading to the establishment of a new dyke called the Wendish Dyke. The southern border of the Angles was marked by the marshes surrounding the Eider, that combined with the dense old-growth forest to the south of the river, formed a natural barrier. South of the forest lay the region now known as Holstein, which was divided between the Germanic Saxons, who inhabited the western part, and the Slavic Wagri, who lived in the eastern part. In the 8th century, the Wagri became part of the Slavic tribal confederation known as the Obotrites (also known as the Wends by the Danes and Saxons). During the 4th and early 5th centuries, a significant migration saw the Jutes, Angles, and Saxons depart from their homelands to settle in the British Isles. This mass exodus left much of the Jutland Peninsula sparsely populated, allowing the Danes from southern Scandinavia and the islands of Zealand, Funen, and other smaller Danish isles to migrate into the peninsula. They gradually settled the region, integrating the remaining Jutes and Angles who had not left for Britain. By the mid-5th century, the Danes had established settlements from Grenen in the north to just north of the Eider River and its marshes.
Microanalysis is the chemical identification and quantitative analysis of very small amounts of chemical substances (generally less than 10 mg or 1 ml) or very small surfaces of material (generally less than 1 cm2). One of the pioneers in the microanalysis of chemical elements was the Slovenian-Austrian Nobel Prize winner Fritz Pregl.
=== Chemical bonds === A fatty acid is characterized as either saturated or unsaturated based on the respective absence or presence of C=C double bonds in its backbone. If the molecule contains no double C=C bonds, it is said to be saturated; otherwise, it is unsaturated to some degree. The C=C double bond is rotationally rigid. If the hydrogen atoms bonded to each of the carbons in this double bond are on the same side, this is called cis, and leads to a bent molecular chain. If the two hydrogens are on opposite sides, this is called trans, and leads to a straight chain.
Sources: en.wikipedia.org
=== 4 September === One person was killed in an SAF drone strike on a market in Manawashi, South Darfur. The drone responsible was shot down by the RSF over Mershing, with RSF commanders claiming that it was a Baykar Bayraktar Akıncı drone.
== History == 1939: Ortho Products, Inc., is formed in Linden, New Jersey, as a division of Johnson & Johnson. 1944: Philip Levine, in the field of hematology, joins Ortho Products to continue his research into the mechanics of the Rh system in human blood. 1997: Ortho Diagnostics Systems and Johnson & Johnson Clinical Diagnostics merge and begin operating as Ortho Clinical Diagnostics. 2001: Ortho becomes the first diagnostic company to receive US FDA approval for automated random access hepatitis tests. 2006: Ortho launches the first FDA-licensed test to screen blood donations for exposure to Chagas disease. 2014: The Carlyle Group acquires Ortho Clinical Diagnostics for $4.15 billion. 2015: Ortho receives FDA clearance for its ORTHO VISION Analyzer, which automates the full range of immunohematology testing and helps improve the safety of blood transfusions by reducing laboratories' reliance on manual methods. 2017: FDA approves Ortho's HIV Combo test for the Vitros immunodiagnostic system. The test detects both HIV-1 and HIV-2 antibodies and the p24 antigen, and enables detection of HIV-1 acute infection earlier than previous assays. 2021: Quidel announced it would acquire Ortho Clinical Diagnostics Holdings for $6 billion in cash and stock, increasing the range of COVID-19 antigen and antibody tests the business is able to offer.
Methylnaltrexone (MNTX, brand name Relistor), used in form of methylnaltrexone bromide (INN, USAN, BAN), is a medication that acts as a peripherally acting μ-opioid receptor antagonist that acts to reverse some of the side effects of opioid drugs such as constipation without significantly affecting pain relief or precipitating withdrawals. Because MNTX is a quaternary ammonium cation, it cannot cross the blood–brain barrier, and so has antagonist effects throughout the body, counteracting effects such as itching and constipation, but without affecting opioid effects in the brain such as pain relief. However, since a significant fraction (up to 60%) of opioid analgesia can be mediated by opioid receptors on peripheral sensory neurons, particularly in inflammatory conditions such as arthritis, traumatic or surgical pain, MNTX may increase pain under such circumstances.
Actor Bill Cosby admitted in a 2015 civil deposition to giving methaqualone to women before allegedly sexually assaulting them. Film director Roman Polanski was convicted in 1977 of sexually assaulting a 13-year-old girl after giving her alcohol and methaqualone.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.